Join us   Log in  


FRONTIERS IN MEDICAL CASE REPORTS - Volume 2; Issue 6, (Nov-Dec, 2021)

Pages: 1-08

Emphysematous Gastritis Secondary to Gastric Mucormycosis in A COVID-19 Positive Patient: Case Report

Islas Torres Martin, Castillo Luna Ana Laura, Rodriguez Moreno José Juan, Rendon Muñoz Valeria Priscilla, Zamora Inzunza José Gerardo, Ibarra Trejo Albert Antonio

Category: Surgical Case Reports

Download PDF


Mucormycosis is an invasive fungal infection with high mortality, which occurs mostly in immunocompromised patients. It is characterized by necrotizing vasculitis and the presence of branching wide-angle hyphae. The gastrointestinal form is one of the rarest, symptoms are nonspecific and only 25% are diagnosed premortem. Treatment consists of antifungal therapy and urgent surgical debridement. Case report: 69-year-old male with a history of type 2 diabetes mellitus presents with dyspnea, SARS CoV2 rapid antigen test turns out positive. During his hospital stay he presents sepsis, gastrointestinal bleeding and pneumoperitoneum on abdominal CT. The patient underwent exploratory laparotomy, necrosis of the greater curvature of the stomach was found, therefore vertical gastrectomy was performed. The histopathological report revealed panmural necrosis associated with arterial thrombosis secondary to Mucor spp, liposomal amphotericin B was started, however, the patient developed nosocomial urinary tract and pulmonary infections, decease was documented 29 days after admission. Conclusion: Mucormycosis is an emerging fungal infection that requires high suspicion for its diagnosis. Antifungals and urgent surgical debridement by the general surgeon are the cornerstone treatment for this entity.

Keywords: Gastrointestinal Mucormycosis, Emphysematous Gastritis, Vertical Gastrectomy, COVID, Case Report


Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: Early diagnosis and successful management. AJR Am J Roentgenol 1985; 145: 739–741.

Alvarado-Lezama J, Espinosa-González O, García-Cano E, Sánchez-Córdova G. Gastritis enfisematosa secundaria a mucormicosis gástrica. Cirugía y Cirujanos 2015; 83: 56-60.

Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503- 509.

Cornely O, Arikan?Akdagli SE, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano LI, Skiada A, Akova M, Arendrup MC. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20: 5–26.

Dioverti MV, Cawcutt KA, Abidi M, Sohail MR, Walker RC, Osmon DR. Gastrointestinal mucormycosis in immunocompromised hosts. Mycoses 2015; 58: 714–718.

Ghuman SS, Sindhu P, Buxi TB, Sheth S, Yadav A, Rawat KS, Sud S. CT appearance of gastrointestinal tract mucormycosis. Abdom Radiol 2021; 46: 1837-1845.

Ho YH and Singh N. MUcormycosis: Its contemporary face and management strategies. Lancet Infect Dis 2011; 11: 301-311.

Jung JH, Cjoi HJ, Yoo J, Kang SJ, Lee KY. Emphysematous gastritis associated with invasive gastric mucormycosis: A case report. J Korean Med Sci 2007; 22: 923-927.

Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O, French Mycosis Study Group. A global analysis of mucormycosis in France: The RetroZygo Study (2005–2007). Clin Infect Dis 2012; 54: S35–S43.

Martinello M, Nelson A, Bignold L, Shaw D. “We are what we eat” Invasive intestinal mucrmycosis: A case report and a review of literature. Med Mycol 2012; 1: 52-55.

Monte Junior ESD, Santos MELD, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, Funari MP, de Moura EGH. Mucormicosis gastrointestinal rara y fatal (cigomicosis) en un paciente con COVID-19: reporte de un caso. Endoscopia clínica 2020; 53: 746–749.

Quiroz N, del Pilar Villanueva J, Lozano EA. Mucormicosis. Rev Asoc Colomb Dermatol 2017; 25: 284-293.

Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. Healthcare-associated mucormycosis. Clin Infect Dis 2012; 54: S44–S54.

Serris A, Danion F, Lanternier F. Disease Entities in Mucormycosis. J Fungi 2019; 5: 23.

Spellberg B. Gastrointestinal mucormycosis. An evolving disease. Gastroenterol Hepat 2012; 1: 52-55.